• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,094
80
61
58
47

COUNTRY

56
17
8
6
5

CATEGORIES

  • 89
  • 129
  • 72
  • 72
  • 43
  • 43
  • 21
  • 17
  • 20
  • 22

PRICE

547
798
1,612
2,579

PUBLISHED

82
299
724
2,579

PRODUCT TYPE

2,433
71
62
12
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Antibodies Triple Analysis: Melanoma, Prostate Cancer and Antibodies - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Breast Cancer, Melanoma and Apoptosis Triple Analysis: Breast Cancer, Melanoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Colorectal Cancer, Leukemia and Melanoma Triple Analysis: Colorectal Cancer, Leukemia and Melanoma - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Leukemia and Melanoma

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Antibodies Triple Analysis: Leukemia, Melanoma and Antibodies - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Lymphoma, Melanoma and Pancreatic Cancer Triple Analysis: Lymphoma, Melanoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Lymphoma, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Lymphoma, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Melanoma, Pancreatic Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Apoptosis Triple Analysis: Melanoma, Prostate Cancer and Apoptosis - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies - Product Thumbnail Image

Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific...

June 2013
FROM
Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Breast Cancer, Melanoma and Peptides Triple Analysis: Breast Cancer, Melanoma and Peptides - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Peptides

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Colorectal Cancer, Melanoma and Peptides Triple Analysis: Colorectal Cancer, Melanoma and Peptides - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Melanoma and Peptides

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Prostate Cancer Triple Analysis: Leukemia, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Angiogenesis Triple Analysis: Leukemia, Melanoma and Angiogenesis - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Peptides Triple Analysis: Lung Cancer, Melanoma and Peptides - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Peptides

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts...

June 2013
FROM
Triple Analysis: Lymphoma, Melanoma and Peptides Triple Analysis: Lymphoma, Melanoma and Peptides - Product Thumbnail Image

Triple Analysis: Lymphoma, Melanoma and Peptides

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Melanoma, Pancreatic Cancer and Apoptosis Triple Analysis: Melanoma, Pancreatic Cancer and Apoptosis - Product Thumbnail Image

Triple Analysis: Melanoma, Pancreatic Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

June 2013
FROM
Loading Indicator

Our Clients

Our clients' logos